Oral Vitamin K for Warfarin Associated Coagulopathy

PHASE3CompletedINTERVENTIONAL
Enrollment

690

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

January 31, 2007

Conditions
CoagulationBleedingThrombosis
Interventions
DRUG

Phytonadione (Vitamin K1)

1.25 mg given orally

Trial Locations (15)

21100

Dept. Internal Medicine, University of Insubria, Varese

42100

Medicina I^- Centro Emostasi E Trombosi -Arcispedale S. Maria Nuova,, Reggio Emilia

80234

Kaiser Permanente of Colorado Clinical Pharmacy, Westminster

87106

University of New Mexico Health Sciences Center, Albuquerque

90127

AOU Policlinico di Palermo, Palermo

169608

Singapore General Hospital, Singapore

B3H 2Y9

Queen Elizabeth II Health Health Sciences, Halifax

L8L 2X2

Hamilton General Hospital, Hamilton

L8N 3Z5

McMaster University, Hamilton

L8N 4A6

St. Joseph's Hospital, Hamilton

L8V 1C3

Henderson Hospital, Hamilton

N6A 4G5

London Health Sciences Centre, London

K1Y 4E9

The Ottawa Hospital Civic Campus, Ottawa

M4N 3M5

Sunnybrook and Women's College Health Sciences Centre, Toronto

H3T 1E2

SMBD Jewish General Hospital, Montreal

All Listed Sponsors
collaborator

McMaster University

OTHER

lead

St. Joseph's Healthcare Hamilton

OTHER

NCT00143715 - Oral Vitamin K for Warfarin Associated Coagulopathy | Biotech Hunter | Biotech Hunter